Bristol Myers Squibb will acquire Mirati Therapeutics in a transaction that values the oncology developer at up to $5.8 billion, the latest example of a drugmaker targeting deals to replenish revenue as top-selling products face competition from generics.
A new study suggests people taking injected medications for weight loss, including Wegovy, Ozempic, Saxenda and Victoza, may be at higher risk for serious digestive problems such as stomach paralysis, pancreatitis, and bowel obstructions.
Sanofi agreed to pay Teva Pharmaceutical Industries Inc. as much as $1.5 billion to help develop and sell a medicine for inflammatory bowel disease, its second deal to gain a new experimental treatment this week.
Pharmaceutical giants including Amgen, Merck and Gilead formed a coalition Wednesday to lobby against a proposed overhaul of federal antitrust guidelines.